The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Opus Genetics Secures $155 Million Financing to Advance Gene Therapy Pipeline

Key Facts

1Opus Genetics signed a strategic financing agreement with Oberland Capital worth up to $155 million.

2The financing includes a $35 million upfront payment and a $5 million equity investment, extending the company's cash runway into 2029.

3Funds will be used to accelerate gene therapy programs for inherited retinal diseases and support upcoming clinical trials.

Create Free Account

Version History

1 additional source confirmed this story

Opus Genetics (Nasdaq: IRD) has entered into a strategic financing agreement with Oberland Capital worth up to $155 million. The deal includes an immediate $35 million upfront payment and a $5 million equity investment, significantly boosting the company's balance sheet. This capital injection is expected to extend the biotech firm's operational cash runway through 2029. The funds are earmarked for accelerating clinical programs targeting inherited retinal diseases and supporting upcoming trials. By securing largely non-dilutive funding, Opus Genetics reduces the immediate pressure for equity raises while advancing its manufacturing and commercialization goals. This strategic move positions the company to achieve key clinical milestones over the next several years.